Altimmune, Inc.
NASDAQAltimmune heads into the post-earnings period with nearly half its float sold short and a lending market that has loosened sharply — a combination that makes the stock one of the more structurally charged setups in small-cap biotech right now. Short interest is the dominant story here. Nearly 49% of the free float is sold short — a level that has held remarkably stable for six…
Snapshot as of 26 Aug 2026
Altimmune heads into the post-earnings period with nearly half its float sold short and a lending market that has loosened sharply — a combination that makes the stock one of the more structurally charged setups in…
Altimmune enters July with one of the most heavily shorted positions in small-cap biotech, even as the stock edges higher and insiders continue to put their own money in. Short interest is the defining story here, and…
Altimmune enters the back half of May with its highest-conviction clinical catalyst in years, yet short sellers have barely flinched — a striking standoff between data momentum and a deeply entrenched bear camp. Short…
Altimmune just reported Q1 results, beat its EPS estimate, and simultaneously saw short sellers add aggressively — a setup that puts the stock in a genuinely unusual position heading into what comes next. The short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALT — free to start on ORTEX.
Sign up for free →Open ALT on ORTEX